| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 10/17/2001 | EP1143965A1 Carbocyclic potassium channel inhibitors |
| 10/17/2001 | EP1143963A1 Multiparticulate bisoprolol formulation |
| 10/17/2001 | EP1143932A1 Transnasal transport/immunisation with highly adaptable carriers |
| 10/17/2001 | CN1072929C Transdermal system for simultaneous delivery of a number of active principles |
| 10/16/2001 | US6303640 Administering oxazole or thiazole derivative compound for reducing side effects of diabetic therapy |
| 10/16/2001 | US6303637 For therapy of autoimmune disease, prophylaxis of resistance to transplantation or transplantation rejection of organs or tissues; suppressing immune system |
| 10/16/2001 | US6303634 Therapy and prophylaxis of breast cancer in a human by administering to human benzothiophene derivative |
| 10/16/2001 | US6303624 Preventives and remedies for hyperphosphatemia |
| 10/16/2001 | US6303591 For therapy of cushing's syndrome or depression |
| 10/16/2001 | US6303314 T-cell receptor Vβ-Dβ-Jβ sequence and methods for its detection |
| 10/16/2001 | US6303146 Solid oral dosage form comprising a combination of metformin and glibenclamide |
| 10/16/2001 | CA2096350C Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth) |
| 10/16/2001 | CA2001774C Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
| 10/11/2001 | WO2001074896A1 Human polynucleotides, polypeptides, and antibodies |
| 10/11/2001 | WO2001074846A2 Peptides mimicking the biological activity of steroid hormones and their uses |
| 10/11/2001 | WO2001074844A2 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity |
| 10/11/2001 | WO2001074840A2 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregna 21-substituted 19-norpregnadienedione as antiprogestational agents |
| 10/11/2001 | WO2001074839A2 Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use |
| 10/11/2001 | WO2001074835A1 O-glucosylated benzamide sglt2 inhibitors and method |
| 10/11/2001 | WO2001074775A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands |
| 10/11/2001 | WO2001074448A1 Stable thyroid hormone preparations and method of making same |
| 10/11/2001 | WO2001074377A1 Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy |
| 10/11/2001 | WO2001074360A1 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 10/11/2001 | WO2001074180A1 Nutritional supplements for stimulating bone growth |
| 10/11/2001 | WO2001025269A3 Human g-protein coupled receptor |
| 10/11/2001 | WO2001007470A3 Human nervous system-associated proteins |
| 10/11/2001 | WO2000076556A3 High dose radionuclide complexes for bone marrow suppression |
| 10/11/2001 | CA2404869A1 Peptides mimicking the biological activity of steroid hormones and their uses |
| 10/11/2001 | CA2404592A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands |
| 10/11/2001 | CA2404376A1 O-glucosylated benzamide sglt2 inhibitors and method |
| 10/11/2001 | CA2404369A1 Stable thyroid hormone preparations and method of making same |
| 10/11/2001 | CA2404074A1 Human polynucleotides, polypeptides, and antibodies |
| 10/11/2001 | CA2402416A1 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity |
| 10/11/2001 | CA2401854A1 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 10/10/2001 | EP1142889A1 Pyrazole derivatives as anti-inflammatory/analgesic agents |
| 10/10/2001 | EP1142582A1 Use of FSH for treating infertility |
| 10/10/2001 | EP1141332A1 Human cyclic nucleotide pdes |
| 10/10/2001 | EP1141286A1 Cytokine receptor chain |
| 10/10/2001 | EP1141240A1 Use of cd40 engagement to alter t cell receptor usage |
| 10/10/2001 | EP1141020A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 10/10/2001 | EP1141015A1 Insulin-like growth factor (igf) i mutant variants |
| 10/10/2001 | EP1141014A1 Insulin-like growth factor (igf) i mutant variants |
| 10/10/2001 | EP1140972A1 New 7-alpha, 17-alpha-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases |
| 10/10/2001 | EP1140960A1 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| 10/10/2001 | EP1140945A1 Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| 10/10/2001 | EP1140931A1 5ht1 antagonists for antidepressant therapy |
| 10/10/2001 | EP1140889A2 Compounds and methods for modulation of estrogen receptors |
| 10/10/2001 | EP1140784A2 Ion channel modulating agents |
| 10/10/2001 | EP1140201A2 Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| 10/10/2001 | EP1140148A1 Shelf-stable formulation of glucagon-like peptide-1 |
| 10/10/2001 | EP1140145A2 Novel exendin agonist formulations and methods of administration thereof |
| 10/10/2001 | EP1140132A1 Gonadotropin releasing hormone antagonist |
| 10/10/2001 | EP1140118A1 Cyclic adenosine diphosphate ribose analogues for modulating t cell activity |
| 10/10/2001 | EP1140111A1 Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide |
| 10/10/2001 | EP1140110A2 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions |
| 10/10/2001 | EP1140047A2 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs |
| 10/10/2001 | EP1140038A1 Transdermal drug delivery system |
| 10/10/2001 | EP1140020A1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 10/10/2001 | EP0830372B1 Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability |
| 10/10/2001 | EP0765320B1 Benzimidazolone derivatives with central dopaminergic activity |
| 10/10/2001 | CN1316991A Azetidine derivatives, preparation and medicines containing them |
| 10/10/2001 | CN1316908A Neuroprotection |
| 10/10/2001 | CN1316246A Application of tea polyphenol in treating thyroid disease |
| 10/10/2001 | CN1072645C Novel 2,3,5-trimethyl-4-hydroxy radical-N-acid aniline derivatives and preparation method and use thereof |
| 10/09/2001 | US6300313 Means for treating prostate hypertrophy and prostate cancer |
| 10/04/2001 | WO2001073034A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 10/04/2001 | WO2001072977A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 10/04/2001 | WO2001072836A2 G-protein coupled receptors |
| 10/04/2001 | WO2001072830A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 10/04/2001 | WO2001072826A2 Oncogenic osteomalacia-related gene 1 |
| 10/04/2001 | WO2001072778A2 Method of identifying inhibitors of tie-2 |
| 10/04/2001 | WO2001072777A2 Human transcription factors |
| 10/04/2001 | WO2001072770A1 Insulin potentiating peptides |
| 10/04/2001 | WO2001072767A1 Dehydroepiandrosterone derivatives, preparation method and uses thereof, in particular for cosmetics |
| 10/04/2001 | WO2001072747A1 Crystalline form ii of cabergoline |
| 10/04/2001 | WO2001072746A1 Crystalline form vii of cabergoline |
| 10/04/2001 | WO2001072713A1 Non-steroidal, tetracyclic compounds for estrogen-related treatments |
| 10/04/2001 | WO2001072692A1 Malonamic acids and derivatives thereof as thyroid receptor ligands |
| 10/04/2001 | WO2001072328A2 Methods of treating diseases with activated protein c |
| 10/04/2001 | WO2001072301A1 Intracorporeal medicaments for photodynamic treatment of disease |
| 10/04/2001 | WO2001072293A2 Antiprogestins with partial agonist activity |
| 10/04/2001 | WO2001072290A2 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 10/04/2001 | WO2001072283A1 Cationic liposomes |
| 10/04/2001 | WO2001019361A3 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 10/04/2001 | WO2001016319A3 Compositions and methods for the treatment of immune related diseases |
| 10/04/2001 | WO2001013957A3 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 10/04/2001 | WO2001000244A3 METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
| 10/04/2001 | WO2000039279A9 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 10/04/2001 | US20010027216 Method for preventing hormone induced adverse effects |
| 10/04/2001 | US20010027212 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 10/04/2001 | EP1137667A2 Analogues of glp-1 |
| 10/04/2001 | EP1137666A1 Glp-1 analogues |
| 10/04/2001 | EP1137658A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES |
| 10/04/2001 | EP1137631A1 REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE |
| 10/04/2001 | EP1137413A2 Non-peptide antagonists of glp-1 receptor and methods of use |
| 10/04/2001 | EP1137402A1 Phospholipid compositions |
| 10/04/2001 | EP1137400A1 Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period toff, verfahren zu seiner herstellung und anlage zur durchfuhrung des verfahrens |
| 10/04/2001 | CA2404570A1 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 10/04/2001 | CA2404532A1 Method of identifying inhibitors of tie-2 |
| 10/04/2001 | CA2404231A1 Methods of treating diseases with activated protein c |